Sildenafil for bronchopulmonary dysplasia‐associated pulmonary hypertension: A systematic search and narrative synthesis
Pediatrics International · 2026-01 · 68 (1)
DOI: 10.1111/ped.70385 ↗At a glance
Systematische Übersicht in Pediatrics International, published online on 2026-04-07. Written by Yoshinori Katayama and 7 co-authors. Institution: Clinical Research Center, Takatsuki General Hospital, Osaka, Japan. Major MEDLINE topics: Bronchopulmonary Dysplasia, Sildenafil Citrate, Hypertension, Pulmonary, Vasodilator Agents. 32 references. Funded by: Health and Labor Sciences Research Grant.
Abstract (original language)
Background
Although sildenafil is commonly used for bronchopulmonary dysplasia‐associated pulmonary hypertension (BPD‐PH), high‐quality evidence to justify its use remains sparse. Thus, we evaluated the efficacy and safety of sildenafil in preterm infants with BPD or BPD‐PH.
Methods
A systematic review of randomized and non‐randomized comparative studies identified by searching MEDLINE, Embase, Cochrane Central Register of Controlled trials, Cumulative Index to Nursing and Allied Health Literature, and Ichushi‐Web until November 28, 2024. The primary outcome measure was mortality at the time of neonatal intensive care unit (NICU) discharge.
Results
Among the 1944 studies identified, 54 were eligible for full‐text screening; however, none met the systematic review criteria. A post hoc narrative synthesis summarized the outcomes of preterm BPD‐PH infants receiving sildenafil in nine studies, which were ineligible for the systematic review due to the lack of control groups. These studies included 15–666 infants born in high‐income countries from 2001 to 2022. Sildenafil treatment improved the PH symptoms in 47%–77% of patients according to the echocardiographic findings. In patients receiving sildenafil, mortality before NICU discharge was 13%–35% and the rate of severe retinopathy of prematurity was 16%–57%.
Conclusions
Evidence to support the use of sildenafil treatment for preterm infants with BPD‐PH to improve mortality and morbidity is lacking. More research, particularly randomized controlled trials, on the efficacy and safety of sildenafil treatment for preterm BPD‐PH infants is needed.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Clinical Research Center, Takatsuki General Hospital, Osaka, Japan.
- Department of Neonatal Medicine, Osaka Women's and Children's Hospital, Osaka, Japan.
- Department of General Perinatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
- Department of Neonatal Medicine, Jichi Medical University Saitama Medical Center, Saitama, Japan.
- Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
- Division of Health Policy, National Center for Child Health and Development, Tokyo, Japan.
ORCID profiles: Yoshinori Katayama, Katsuya Hirata, Atsuko Nakahari
Funding
- Health and Labor Sciences Research Grant
Cite
APA
Katayama, Y., Hirata, K., Nishimura, Y., Nakahari, A., Takeoka, M., Watanabe, M., Isayama, T., & Japan Evidence Based Neonatology (JEBNeo) (2026). Sildenafil for bronchopulmonary dysplasia‐associated pulmonary hypertension: A systematic search and narrative synthesis. Pediatrics International, 68(1). https://doi.org/10.1111/ped.70385
Vancouver
Katayama Y, Hirata K, Nishimura Y, Nakahari A, Takeoka M, Watanabe M, et al. Sildenafil for bronchopulmonary dysplasia‐associated pulmonary hypertension: A systematic search and narrative synthesis. Pediatrics International. 2026;68(1). doi:10.1111/ped.70385
BibTeX
@article{Katayama2026,
author = {Katayama, Yoshinori and Hirata, Katsuya and Nishimura, Yutaka and Nakahari, Atsuko and Takeoka, Mami and Watanabe, Masahiko and Isayama, Tetsuya and Japan Evidence Based Neonatology (JEBNeo), Japan Evidence Based Neonatology (JEBNeo)},
title = {Sildenafil for bronchopulmonary dysplasia‐associated pulmonary hypertension: A systematic search and narrative synthesis},
journal = {Pediatrics International},
year = {2026},
volume = {68},
number = {1},
doi = {10.1111/ped.70385}
}
EUVIMED